文献速递免疫规划传染病防控与疫情报告

HBI灭活甲肝疫苗在健康青少年与成人中的安全性与免疫原性Ⅰ期研究

Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study.
PubMed 文献 · Vaccine · 2021-03-17

该Ⅰ期单臂开放标签多中心试验在印度两个中心纳入55名健康受试者,分19-49岁组和12-18岁组,单剂接种HBI灭活甲肝疫苗。接种后4-6周,15例报告不良事件,无严重不良事件,两组均达100%血清阳转和血清保护,抗体滴度显著升高。结论为该疫苗在青少年和成人中安全且免疫原性高。

要点

  • 单剂HBI灭活甲肝疫苗在19-49岁和12-18岁健康人群中均达100%血清阳转和血清保护。
  • 55名受试者中15例报告不良事件,无严重不良事件,局部不良事件仅注射部位疼痛。
  • A组报告乏力、头痛、腹泻、发热、食欲减退、恶心和上呼吸道感染,B组无全身不良事件。

核心结论

  • HBI灭活甲肝疫苗在青少年和成人中单剂接种安全且免疫原性高。

研究设计与样本

  • Ⅰ期单臂开放标签多中心试验,在印度两个中心纳入55名健康受试者。
  • A组为19-49岁受试者,B组为12-18岁受试者,均接种单剂灭活甲肝疫苗。
  • 基线和接种后4-6周采血,评估不良事件、血清阳转率、血清保护率和抗体几何平均滴度。

主要发现

  • 55名受试者中15例报告不良事件,无严重不良事件报告。
  • 局部不良事件仅注射部位疼痛。
  • A组报告乏力、头痛、腹泻、发热、食欲减退、恶心和上呼吸道感染,B组无全身不良事件报告。
  • 两组接种后均观察到100%血清阳转和血清保护,抗体滴度水平显著升高。

临床怎么用

  • 该Ⅰ期结果支持HBI灭活甲肝疫苗在青少年和成人中单剂接种的安全性和免疫原性,但需后续研究验证。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis-A is an acute viral infection of the liver. Hepatitis-A virus has worldwide spread and is endemic in India. Though the disease is self-limiting in most cases, outbreaks are reported frequently from both developing and developed countries of the world. Severity and fatality occur more among infected symptomatic adults. The infection can be prevented with proper and timely immunization. This phase I, single arm, open label, multicenter trial was designed to assess the safety and immunogenicity of the inactivated hepatitis-A vaccine developed by Human Biologicals Institute when administered in a single dose in two age groups of healthy subjects. METHODS: This study was carried out in 55 subjects in two healthy age groups at two centers in India. Group A included subjects of 19-49 years and group B subjects of 12-18 years of age. Enrolled subjects received a single dose of inactivated hepatitis A vaccine. Blood samples were collected at baseline and 4-6 weeks after vaccination. Safety was assessed by collection and analysis of data on solicited and unsolicited adverse events and immunogenicity was assessed by estimating the seroconversion rate, seroprotection rate and the geometric mean titres of antibodies. RESULTS: Among the 55 subjects enrolled, 15 reported adverse events. No serious adverse event was reported. Pain at the injection site was the lone local adverse event. Systemic adverse events reported in Group A were: fatigue, headache, diarrhoea, fever, anorexia, nausea and upper respiratory tract infection, whereas there was no systemic event reported in Group B. There was 100% seroconversion and seroprotection and significant rise in antibody titre levels were observed in both the groups post vaccination. CONCLUSIONS: This study found HBI inactivated hepatitis-A vaccine to be safe and highly immunogenic when administered as a single dose in adolescent and adult subjects.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Susarla SK, Palkar S, Sv PS, et al. Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study. Vaccine. 2021. PMID: 33741190. doi:10.1016/j.vaccine.2021.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。